[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-cyst\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-cyst":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,42,74,110,130,153,178,200,232,255,295,321,344,369,391,420,446,475,494],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100540757","phase-1-chemoprevention-with-tamoxifen-in-pre-invasive-pancreas-mucinous-cystic-neoplasms-not-undergoing-immediate-resection-100540757",false,"NCT06320990","Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection","A Pilot Study of Chemoprevention With Tamoxifen in Patients With Pre-Invasive Pancreas Mucinous Cystic Neoplasms Who Will Not Undergo Immediate Resection","MCN_Tam","Inclusion Criteria:\n\n* Age ≥ 19 years\n* Clinically diagnosed pre-invasive pancreatic mucinous cystic neoplasm (MCN), measurable by cross-sectional imaging\n* Surgical resection of the lesion is not planned due to cyst features, patient factors or patient preference\n* Females of reproductive potential and males with partners of reproductive potential must agree to employ two methods contraception throughout the study and for up to 3 months following treatment. Non-child-bearing potential is defined as age 45 years or older and no menses for greater than or equal to 12 months or any age with surgical removal of the uterus and\u002For both ovaries.\n* Estimated glomerular filtration rate (eGFR) \\> 30mL\u002Fmin\u002F1.73m2\n* Willing and able to provide informed consent to and abide by the protocol\n\nExclusion Criteria:\n\n* Presence of invasive pancreatic adenocarcinoma or high-grade dysplasia\n* Presence of a solid component or mural nodule, main pancreatic duct dilation or abrupt caliber change, obstructive jaundice, lymphadenopathy\n* Current or prior use of tamoxifen or another estrogen antagonist including, but not limited to, clomifene, raloxifene, fulvestrant, anastrazole; subjects who have previously used an estrogen antagonist are eligible provided the last use was at least 5 years prior to enrollment.\n* Current or planned use of hormonal treatments including estrogen, progesterone, androgens, hormone replacement therapy or other types of hormonal contraceptives including implants and depot injections; levonorgestrel-releasing intrauterine device (IUD) is permitted.\n* Contraindications to tamoxifen include:\n\n  * Pregnancy or nursing\n  * Known allergy or hypersensitivity to tamoxifen\n  * Cataracts which affect visual acuity (ie. symptomatic)\n  * Retinopathy which affects visual acuity (ie. symptomatic)\n  * Current warfarin use\n  * History of deep vein thrombosis or pulmonary embolism or other condition which, in the opinion of the investigator, may significantly increase the individual's risk of venous thromboembolism\n  * History of stroke\n  * Known endometrial hyperplasia or personal history of endometrial carcinoma, uterine sarcoma and uterine carcinosarcoma\n* History of intestinal disease or major gastric surgery likely to alter absorption of tamoxifen or inability to swallow oral medications\n* Uncontrolled illness including but not limited to ongoing or active infection requiring IV antibiotics, symptomatic congestive heart failure, unstable angina or uncontrolled cardiac arrhythmias, or other conditions which might jeopardize or preclude the ability of the patient to take tamoxifen or the safety of follow-up visits, scans and procedures\n* Elective surgery planned for the study period\n* Participation in another clinical study with an investigational product during the last 28 days\n* Any participant, in the opinion of the investigator, who will not be able to tolerate treatment, or the participant is unsuitable to participate in the study and is unlikely to comply with study procedures, restrictions and requirements","ALL","19 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","Pancreatic mucinous cystic neoplasm (MCN) is a precursor to invasive pancreatic adenocarcinoma which occurs almost exclusively in females in their 5th-7th decade. Currently the only option for MCN treatment and prevention of invasive pancreatic ductal adenocarcinoma (PDA) is oncologic resection. The clinical features of pancreatic MCN support the influence of sex hormones in the pathogenesis of the disease. Anti-hormonal therapy may therefore constitute an effective approach to treatment. Preliminary analyses from preclinical studies suggest that tamoxifen inhibits the spread and normal life cycle in MCN epithelial cells and fibroblasts. Investigators hypothesize that in humans, treatment with tamoxifen will lead to cyst regression or stabilization and may spare or delay the need for resection. Up to 15 participants not undergoing immediate resection will be enrolled and take tamoxifen orally for up to 24 weeks. The study will assess the feasibility of tamoxifen as a treatment for pancreatic MCN.",[27,28],"Pancreatic Cyst","Pancreatic Mucinous Cystic Neoplasm","RECRUITING","2026-05-11",{"date":32,"type":33},"2026-05-14","ACTUAL",{"date":35,"type":33},"2025-01-22",{"date":37,"type":21},"2029-05",{"name":39,"class":40},"University of Nebraska","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":62,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":41},"100608807","in-depth-characterisation-of-biliary-strictures-and-hepato-pancreato-biliary-focal-lesions-for-development-of-new-technologies-to-tackle-hepato-pancreato-biliary-cancers-100608807","NCT07206355","In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary Cancers","Map HPB","Inclusion Criteria:\n\n* Aged 16 years and over\n* Ability to provide informed consent to participate in the study\n* Patients attending Nottingham University Hospitals NHS Trust (NUH) as part of standard clinical care for either:\n\n  * the diagnosis and treatment of suspected biliary stricture or any focal lesion in the Hepato-Pancreato-Biliary (HPB) tract (clinically \u002F radiologically) including liver or pancreatic lesion or pancreatic cyst\n  * surgical resection treatment of liver, pancreas, or gall bladder including Whipple Procedure (pancreaticoduodenectomy surgery), gall bladder resection (cholecystectomy), hepatic resection\n\nExclusion Criteria: No exclusion criteria","16 Years",{"count":51,"type":21},160,"5 Years","OBSERVATIONAL","Hepato-Pancreato-Biliary (HPB) cancers originating in the liver, bile ducts, pancreas, and gall bladder represent a rising global health challenge, with incidence doubling in the UK over the past decade. Cholangiocarcinoma (CCA) and pancreatic cancer are particularly aggressive, often detected late due to non-specific symptoms and difficulties in sampling or imaging. In the UK, CCA affects around 3,000 people annually, with only 13% surviving 3 years, while pancreatic cancer has a 5-year survival of 8.3%. Diagnosis is complicated by the anatomical narrowness of the bile duct and the similarity between malignant and benign strictures. Standard imaging often cannot distinguish between inflammation and cancer, while tissue sampling is challenging, paucicellular, and limited in sensitivity, necessitating repeated biopsies. Yet, accurate characterisation is critical as NICE now recommends targeted therapies (FGFR2, NTRK, MSI-H\u002FdMMR, IDH1 mutations) that require molecular profiling.\n\nBoth CCA and PDAC display high heterogeneity, further complicating treatment. Emerging approaches such as Raman spectroscopy can map malignant tissues by detecting vibrational energy shifts, but require further validation due to weak signals. For focal or cystic HPB lesions not well visualised by conventional imaging, novel modalities like ultra-thin endoscopes with scattering\u002Fabsorption imaging are being developed for improved early diagnosis.\n\nManagement of biliary obstruction frequently involves stenting to restore bile flow, essential for palliation and pre-treatment optimization. However, stent failure from tumour ingrowth, displacement, or erosion remains common, and evidence for best stent use is limited. Novel approaches, including drug-eluting coatings and nanoparticle-mediated wireless treatment delivery, are being investigated.\n\nTo overcome diagnostic and therapeutic barriers, flexible snake-like robotic systems with navigation, sampling, spectroscopy, and treatment capabilities are being developed. These devices, alongside ultra-thin endoscopes and integrated Raman spectroscopy, aim to characterise strictures, generate 3D imaging in ex-vivo HPB tissue, and permit targeted ablation. Parallel work will explore molecular and fluid-based biomarkers (blood, bile, cyst fluid) to support minimally invasive diagnosis and monitoring.\n\nThrough integration of engineering, molecular diagnostics, and device innovation, this transdisciplinary research programme (UKRI and MRC funded) seeks to transform early detection, accurate diagnosis, and novel treatment of HPB cancers, thereby improving outcomes in CCA, pancreatic malignancy, and other clinically similar biliary disorders.\n\nAim:\n\nTo provide a detailed understanding of the characteristics (including clinical and molecular) of liver and pancreatic biliary focal lesions (inflammatory and cancerous) and create a bioresource of liver, pancreas, gallbladder and biliary tract associated tissue and fluids (biopsies, brushings, resected tissues, bile and cyst fluid and blood samples) in order to develop innovative tools for accurate diagnosis and treatment.\n\nStudy Configuration: Prospective Longitudinal Cohort study Setting: Secondary care centre, Nottingham University Hospitals NHS Trust. (NUH).\n\nCo-ordinated by the NIHR Nottingham Biomedical Research Centre Description of interventions: This is an observational study involving collecting tissue or body fluids (such as bile or pancreatic cyst fluid) during clinical care in addition to collection of blood samples (for DNA, serum and plasma) and data collection.\n\nSurplus tissue residual to the requirements for standard care will be stored and used. Additional tissue samples and body fluid samples collected for research at time of clinical investigations will not be increasing the risk of the clinical procedure.\n\nBlood samples will be collected from patients at the time of enrolment in the study. These may be collected before and\u002F or after diagnosis is secured.\n\nDuration of study: Overall duration: 60 months Outcome measures: - To report the proportion of patients where adequate tissue could be retrieved from HPB biopsy to come to definitive diagnosis using standard of care.\n\n* To report the proportion of patients where adequate tissue could be retrieved from biopsy to perform molecular characterisation of HPB samples, beyond standard cyto\u002Fhistology, using advanced optical-spatial technologies currently under development.\n* To report the proportion of patients where definitive diagnosis of mucinous cystic neoplasm could be made in patients with pancreatic cyst using standard care\n* To report the proportion of patients where molecular characterisation beyond standard cyto\u002Fhistology could be made in patients with pancreatic cyst using exploratory new technologies under development through ex-vivo experiments\n* To report the correlation between Raman Spectroscopy and standard cyto\u002Fhistology for identification of cancer in HPB samples",[56,57,58,59,60,61,27],"Biliary Tract Cancer (BTC)","Biliary Tract Cancer (CCA)","Cholangiocarcinoma","Cholangiocarcinoma Cancer","Cholangio Carcinoma","Pancreatic Cancer",[63,61,27,64,56,58],"biliary tract cancer","Pancreatic lesions","2026-04-28",{"date":67,"type":33},"2026-04-29",{"date":69,"type":33},"2026-01-25",{"date":71,"type":21},"2030-09-30",{"name":73,"class":40},"University of Nottingham",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":84,"studyType":53,"phases":4,"briefSummary":85,"conditions":86,"keywords":92,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100268556","pancreas-registry-and-high-risk-registry-100268556","NCT02775461","Pancreas Registry and High Risk Registry","Pancreas Disease and High Risk Registry","Inclusion Criteria:\n\n* At least 1 first degree relative affected with Pancreatic Cancer\n* Any of (BRCA1, BRCA2, PALB2, ATM) mutations + 1 family member with Pancreatic Cancer\n* mFAMMM (p16,CDKN2A mutations) + 1 family member with Pancreatic cancer\n* Known mutation carrier for STK11 (Peutz Jeghers Syndrome)\n* Lynch syndrome (HNPCC) + 1 family PDAC\n* Known mutation carrier for Hereditary pancreatitis\n* Individuals with a history of pancreatic cyst(s) (IPMN's) that measure ≥ 1 cm\n\nExclusion Criteria:\n\n* Patients who do not speak English or Spanish\n* Refusal by patient\n* Individuals under the age of 18 years","18 Years",{"count":83,"type":21},1368,"10 Years","The purpose of this study is to establish a registry of patients with pancreatic diseases. Patients included in the registry may include those with: pancreatic cancer, precancerous lesions of the pancreas, inflammatory lesions of the pancreas, cystic lesions of the pancreas, and patients at high-risk of pancreatic cancer such as those with a family history of pancreatic cancer or with a family history of a syndrome known to be associated with pancreatic cancer. Pancreatic cancer is the fourth leading cause of death from cancer in the United States. However, little is known about the development of pancreatic cancer and pancreatic diseases in individuals with the above conditions. Knowledge of how family history, environmental exposures, and inflammatory lesion of the pancreas contribute to the development of pancreatic cancer and pancreatic diseases is essential.\n\nYou may qualify to take part in this research study because you have inflammation in the pancreas, a pancreatic cyst, pre-cancerous lesions of the pancreas, pancreatic cancer, a family history of pancreatic cancer, or a family history of a syndrome known to be associated with pancreatic cancer.\n\nWe will also be collecting a blood sample from all participants for DNA isolation. Sometimes we are born with genes or DNA that give us an increased or decreased chance of developing an illness later in life. Genetic material will be isolated from your blood for further study. You may also choose to provide additional blood samples for serum and plasma extraction. Serum and plasma are components of the blood which can be used to measure indicators of disease in the blood, called biomarkers,for pancreatic diseases. Clinical data and biological specimens contained in this study may be used for a wide variety of future related studies to the cause, diagnosis, outcome and treatment of pancreatic cancer.\n\nFunds for conducting this research are provided by Mount Sinai.",[87,88,89,27,90,91],"Pancreas Cancer","Pancreatitis","Chronic Pancreatitis","Family History of Pancreas Cancer","Genetic Mutations",[87,89,27,93,94,95,96,97,98,88,90,99],"BRCA1","BRCA2","Lynch Syndrome","Peutz-Jeghers syndrome","ATM mutation","FAMMM Syndrome","Family History of Cancer","2026-02-09",{"date":102,"type":33},"2026-02-11",{"date":104,"type":33},"2013-03-01",{"date":106,"type":21},"2033-01",{"name":108,"class":40},"Icahn School of Medicine at Mount Sinai",2,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":41},"100506385","phase-1-study-using-hyperpolarized-13c-pyruvate-magnetic-resonance-spectroscopic-imaging-in-patients-with-pancreatic-cysts-undergoing-surgical-resection-100506385","NCT05873699","Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection","Pilot Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection","Inclusion Criteria:\n\n* Patients ≥ 18 years old. Patients under 18 are excluded due to their potential inability to understand and consent independently to the methods required for the study drug use and its potential risks and benefits.\n* Patients with pancreatic cyst\u002Fs\n* Patients who will undergo surgical resection (or cyst wall biopsy) of pancreatic cysts\n* Patients able to understand and willing to sign a written informed consent document\n* Both English-speaking and non-English-speaking patients are eligible for participation\n\nExclusion Criteria:\n\n* Contraindication to MRI\n* Electrically, magnetically, or mechanically activated implants that would preclude MRI\n* Allergy to Gadavist IV contrast\n* History of cardiac arrhythmias\n* Pregnancy or breastfeeding women\n* Women of child-bearing age that are sexually active and not using birth control\n* Cognitively impaired individuals\n* Weight above 260 pounds (lbs)",{"count":118,"type":21},20,[24],"To learn if Hyperpolarized C-Pyruvate Magnetic Resonance (HP-MR) Spectroscopic Imaging can help doctors detect low-risk (benign) and high-risk (malignant) cysts.",[27],"2026-02-05",{"date":100,"type":33},{"date":125,"type":33},"2023-08-18",{"date":127,"type":21},"2027-01-31",{"name":129,"class":40},"M.D. Anderson Cancer Center",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":152},"100383661","using-radiogenomics-to-predict-malignant-potential-of-intraductal-papillary-mucinous-neoplasms-of-the-pancreas-100383661","NCT04275557","Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas","Using Radiogenomics to Noninvasively Predict the Malignant Potential of Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas and Uncover Hidden Biology","Inclusion Criteria:\n\n* Individuals who present to the GI clinic, surgery, or endoscopy at Moffitt, Florida Research Institute (FRI), or UM with a clinical suspicion for (or diagnosis of) a pancreatic lesion, cyst, mass, cancer, or pancreatitis based on symptoms, imaging, or blood-work and has not had any treatment involving their pancreas.\n* Able to understand and voluntarily sign the informed consent.\n* Willing to complete study questionnaire(s) and donate medical images and\u002For biological specimens (including blood, cystic fluid, and\u002For tissue) obtained at the time of standard of care procedures (biopsy, surgery, and venipuncture) after signing the informed consent document\n\nExclusion Criteria:\n\n* No suspicion or diagnosis of a pancreatic lesion, cyst, mass, cancer, or pancreatitis.\n* Has a diagnosis of a pancreatic lesion, cyst, mass, cancer, or pancreatitis and has already undergone treatment involving the pancreas (which may involve surgery, chemo- or immuno-therapy, and\u002For radiation).\n* Unable to provide informed consent.\n* Unwilling to complete study questionnaire(s) and\u002For donate biological specimens or images.",{"count":138,"type":21},1174,"The Florida Pancreas Collaborative wants to partner with individuals who are known to have, or are suspected to have a pancreatic lesion, tumor, cyst, mass, cancer, or pancreatitis and are undergoing diagnosis and treatment at a participating institution. The goals of this project are to build a large database of information obtained from blood, tissue, medical images, surveys and information from routine care to develop noninvasive diagnostic approaches that could be used as decision-making tools to effectively personalize clinical care.",[61,27],[142],"Pancreatic Lesions","2025-12-03",{"date":145,"type":33},"2025-12-04",{"date":147,"type":33},"2020-02-18",{"date":149,"type":21},"2027-06",{"name":151,"class":40},"H. Lee Moffitt Cancer Center and Research Institute",3,{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":160,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":177},"100311460","a-study-of-blood-based-biomarkers-for-pancreas-adenocarcinoma-100311460","NCT03334708","A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma","Development of Biomarkers for the Early Detection, Surveillance and Monitoring of Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\nCohort 1: Advanced Pancreatic Cancer Cohort Inclusion Criteria\n\n* Radiological, histological or cytological confirmed diagnosis of locally advanced or metastatic pancreatic adenocarcinoma by the enrolling institution\n* Patient planning to receive systemic treatment\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n* Willing to undergo a tumor biopsy\n* Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).\n\nCohort 2: Operable Pancreatic Cancer Cohort Inclusion Criteria\n\n* Radiological, histological or cytological confirmed diagnosis of pancreatic adenocarcinoma by the enrolling institution\n* Patient planned to undergo upfront resection\n* No pre-operative systemic therapy nor chemoradiation therapy planned\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n* Willing to undergo a tumor biopsy\n* Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).\n\nCohort 3: Acute Benign Pancreatic Pathology Control Inclusion Criteria\n\n* Confirmed diagnosis of acute pancreatitis or other acute pancreatic pathology by the enrolling institution\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n\nCohort 4: Chronic Benign Pancreatic Pathology Control Inclusion Criteria\n\n* Confirmed diagnosis of chronic pancreatitis or other non-cystic chronic pancreatic pathology by the enrolling institution\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n\nCohort 5: IPMN Control Inclusion Criteria\n\n* Confirmed diagnosis of IPMN without high risk features by the enrolling institution\n* A minimum age of 18 years old\n\nCohort 6: Pancreatic Cyst Control Inclusion Criteria\n\n* Confirmed diagnosis of benign pancreatic cyst by the enrolling institution\n* A minimum age of 18 years old\n\nCohort 7: Healthy Control Inclusion Criteria\n\n* A minimum age of 18 years old\n\nExclusion Criteria:\n\nCohort 1: Advanced Pancreatic Cancer Cohort Exclusion Criteria\n\n* Prior chemotherapy or radiation therapy for pancreatic cancer within the last 3 months in the localized setting\n* Active second malignancy, unless low grade malignancy\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 2: Operable Pancreatic Cancer Cohort Exclusion Criteria\n\n* Neoadjuvant chemotherapy or radiation therapy is planned\n* Active second malignancy, unless low grade malignancy\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 3: Acute Benign Pancreatic Pathology Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 4: Chronic Benign Pancreatic Pathology Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 5: IPMN Control Exclusion Criteria\n\n* IPMN with high risk features or planned resection\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 6: Pancreatic Cyst Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 7: Healthy Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures",true,{"count":162,"type":21},700,"The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.",[61,165,88,27],"Pancreatic Diseases",[167],"17-257","2025-12-01",{"date":170,"type":33},"2025-12-02",{"date":172,"type":33},"2017-10-30",{"date":174,"type":21},"2026-10-30",{"name":176,"class":40},"Memorial Sloan Kettering Cancer Center",13,{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":187,"conditions":188,"keywords":189,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":199},"100539583","hyperpolarized-c-pyruvate-magnetic-resonance-imaging-and-blood-based-biomarkers-for-early-detection-of-pancreatic-adenocarcinoma-in-patients-with-intraductal-papillary-mucinous-neoplasms-100539583","NCT06305728","Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms","Immuno-Positron Emission Tomography, Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms","Inclusion Criteria:\n\n* Men and women aged \\>18 years\n* Pancreatic cystic neoplasm deemed to be high risk and requiring surgical resection\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Pathologic evidence of pancreatic cancer\n* Pregnant or breast-feeding patients\n* Refusal or inability to tolerate scan (eg anxiety or claustrophobia)\n* Inability to lay flat or meet the standard requirements of traditional MRI\n* Hepatic function from assays obtained within 6 weeks prior to the study enrollment. For each patient, the upper limit of normal (ULN) value for a particular assay will be defined by the normal reference values of the laboratory that performed the assay\n\n  1. Bilirubin \\> 1.5 x ULN\n  2. AST\u002FALT \\> 2.5 x ULN\n  3. Albumin \\\u003C 3 g\u002FdL\n  4. GGT \\> 2.5 x ULN if Alkaline Phosphatase \\> 2.5 x ULN\n* Renal function with Creatinine \\> 1.5 x ULN or creatinine clearance \\\u003C 60 mL\u002Fmin, from assays obtained within 6 weeks prior to study enrollment\n* Cardiac: congestive heart failure with New York Heart Association (NYHA) status ≥2, poorly controlled hypertension, a history of clinically significant EKG abnormalities, or myocardial infarction within 6 months of study enrollment.",{"count":186,"type":21},25,"The purpose of this study is for researchers to find ways of detecting pancreatic ductal adenocarcinoma\u002FPDAC early to avoid the invasive procedure of surgery. The study researchers think a combination of imaging and a series of blood tests may be an effective way to detect PDAC early. In this study, researchers will look at whether a combination of the following types of imaging with blood tests can detect PDAC in pancreatic cysts:\n\n* The ImmunoPET scan (immune-positron emission tomography scan) with the imaging agent 89Zr-DFO-HuMab-5B1\n* The HP MRI scan (hyperpolarized pyruvate magnetic resonance imaging scan)",[27],[27,176,190],"23-367","2025-10-08",{"date":193,"type":33},"2025-10-09",{"date":195,"type":33},"2024-03-04",{"date":197,"type":21},"2030-03-04",{"name":176,"class":40},8,{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":208,"targetDuration":84,"studyType":53,"phases":4,"briefSummary":210,"conditions":211,"keywords":217,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":41},"100384895","ucsf-panc-cyst-registry-100384895","NCT04291651","UCSF PANC Cyst Registry","Population-Based Analysis of Neoplastic Changes in Cystic Lesions of the Pancreas.","UCSF PCR","Inclusion Criteria:\n\n* The inclusion criteria for this study are intentionally broad. Eligible patients for prospective enrollment will include\n* Adults ≥ 30 years of age\n* Have a radiographic or endoscopic diagnosis of at least one pancreatic cysts regardless of treatment status,\n* No history of pancreatic cancer,\n* Can speak and read English,\n* Have access to a computer or mobile device (\\~95% of U.S. population); and\n* Are able to complete an electronic informed consent.\n\nExclusion Criteria:\n\n* Patients who don't speak English,\n* Don't have access to a computer or mobile device; or\n* Patients who have a cancer diagnosis.",{"count":209,"type":21},4000,"Pancreatic cysts are found incidentally on 15-50% of CT and MRIs for all indications and their prevalence is increasing. Many of these cysts may be precursors to pancreatic cancer, and thus pose a substantial risk, however, the vast majority are benign. Increased detection of pancreatic cysts provides an opportunity to diagnose pancreatic malignancy at an early, curable stage yet also increases the potential to over-treat clinically insignificant lesions. This presents a clinical challenge to prevent unnecessary resection of indolent disease, with associated risks of infections, bleeding, diabetes, and costly disability. Unfortunately, there is little information on the epidemiology and natural history of pancreatic cysts to help guide management.",[27,212,61,165,213,214,215,216],"Pancreatic Neoplasms","Pancreatic Intraductal Papillary Mucinous Neoplasm","Intraductal Papillary Mucinous Neoplasm","Pancreatic Ductal Adenocarcinoma","Mucinous Cyst",[27,218,61,214,219,220,221,222],"Pancreatic Cystic Lesion","Serous Cystadenoma","Mucinous Cystic Neoplasm","Cancer Epidemiology","Early Detection Research","2025-09-16",{"date":225,"type":33},"2025-09-18",{"date":227,"type":33},"2019-10-08",{"date":229,"type":21},"2030-01-01",{"name":231,"class":40},"University of California, San Francisco",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":240,"targetDuration":242,"studyType":53,"phases":4,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":109},"100606261","proms-after-pancreatectomy-100606261","NCT07173257","PROMs After Pancreatectomy","Patient Reported Outcomes Measures in Patients Undergoing Pancreatic Resections","PERSPECTIVE","Inclusion Criteria:\n\n* Patients \\>18 years old who undergo pancreatic resection for any indication of any race, gender, or ethnicity who are fluent in English\n\nExclusion Criteria:\n\n* \\\u003C18 years old\n* Deemed not to have capacity to consent.",{"count":241,"type":21},250,"2 Years","The standard of care for a patient with resectable pancreatic is to perform pancreatic resection which, even in the modern era is associated with significant complications and impact on quality of life, often in the setting of poor survival even in the best scenario. Currently, there is a lack of data on patient quality of life after such procedures, how quality of life changes throughout the course of care, and whether patients who undergo these procedures are satisfied with their decision. This research is aimed to understand the impact of pancreatic surgery on patients' quality of life, how that impact changes over time, and patient satisfaction (or regret) with their decisions. This work will help improve the pre-operative conversation to help patients decide whether undergoing a pancreatic resection aligns with their post-operative goals of care.",[245,88,27],"Pancreas Neoplasms","2025-09-08",{"date":248,"type":33},"2025-09-15",{"date":250,"type":33},"2023-04-03",{"date":252,"type":21},"2026-12",{"name":254,"class":40},"University of Arizona",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":22,"phases":265,"briefSummary":267,"conditions":268,"keywords":277,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":41},"100588255","laparoscopic-versus-robot-assisted-left-sided-pancreatectomy-for-benign-and-pre-malignant-lesions-diploma-3-100588255","NCT06939023","Laparoscopic Versus Robot-assisted Left-sided Pancreatectomy for Benign and Pre-malignant Lesions (DIPLOMA-3)","Laparoscopic Versus Robot-assisted Left-sided Pancreatectomy for Benign and Pre-malignant Lesions (DIPLOMA-3): an International Multicenter Patient-blinded Randomized Controlled Trial","DIPLOMA-3","Inclusion Criteria:\n\n* Age at least 18 years;\n* Indication for elective left-sided pancreatectomy, either spleen-preserving or non-preserving (because of proven or suspected left-sided benign or premalignant disease);\n* Both robot-assisted and laparoscopic left-sided pancreatectomy are technically feasible for resection, according to the local treatment team;\n* Fit to undergo left-sided pancreatectomy according to the surgeon and anaesthesiologist;\n* Written informed consent\n\nExclusion Criteria:\n\n* Suspected pancreatic ductal adenocarcinoma;\n* Tumor or cyst larger than 8 cm;\n* Required resection or ablation of organs other than pancreas and spleen;\n* Tumor involvement or abutment of major vessels (celiac trunk, mesenteric artery or vena cava);\n* Pregnancy;\n* Body mass index \\>40 kg\u002Fm2;\n* Participation in another study with interference of study outcomes",{"count":264,"type":21},256,[266],"NA","The DIPLOMA-3 trial is an international, multicenter, patient-blinded randomized controlled trial comparing laparoscopic and robot-assisted left-sided pancreatectomy. Patients with an indication for elective left-sided pancreatecomy for benign or premalignant lesions in the body or tail of the pancreas and considered eligible will be randomized between laparoscopic and robot-assisted resection.",[269,270,212,271,27,272,273,274,275,276],"Pancreatectomy","Distal Pancreatectomy (DP)","Pancreatic Adenoma","Pancreatic Cystadenoma","Surgery","Minimally Invasive Surgical Technique","Minimally Invasive Distal Pancreatectomy","Minimally Invasive Surgery",[278,279,280,281,282,283,284,285],"pancreas surgery","left-sided pancreatectomy","distal pancreatectomy","minimally invasive surgery","robot-assisted pancreatectomy","left pancreatectomy","robotic pancreatectomy","laparoscopic pancreatectomy","2025-08-28",{"date":288,"type":33},"2025-09-04",{"date":290,"type":33},"2025-06-01",{"date":292,"type":21},"2028-06-01",{"name":294,"class":40},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":305,"conditions":306,"keywords":307,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":320},"100323530","confocal-laser-endomicroscopy-as-an-imaging-biomarker-for-the-diagnosis-of-pancreatic-cystic-lesions-100323530","NCT03492151","Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions","Confocal Laser Endomicroscopy as an IMaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions","CLIMB","Inclusion Criteria:\n\n* Patient age 18 years or older\n* All patients referred for EUS-FNA of accessible PCL where surgery is contemplated\n* Minimum cyst size should be ≥ 2.0 cm as determined by prior cross-sectional imaging studies\n\nExclusion Criteria:\n\n* Unable to obtain informed consent\n* Unable to tolerate the procedure\n* Women with known pregnancy at time of procedure\n* Patient age less than 18 years\n* Bleeding diathesis\n* Known allergy to fluorescein\n* Prior pancreatic cancer\n* Prior pancreatic surgery",{"count":304,"type":21},500,"The study schema is shown in Figure 4. (A) All patients referred to one of the participating academic centers for EUS evaluation of the PCL will be enrolled in the protocol if they satisfy inclusion criteria. Patient consent will be obtained during the clinic visit or prior to their EUS. EUS-guided nCLE imaging is first performed (B) followed by EUS-guided FNA and aspiration of cyst fluid. The cyst fluid is analyzed for CEA and cytology. As per institutional standard of care, the cyst fluid is also sent for molecular analysis. The results of the cyst fluid molecular analysis (B) will be utilized for the most likely diagnosis. Based on institutional multidisciplinary tumor board meetings, surgery is performed as indicated (C). Surgical histopathology serves as \"gold standard\" for diagnosis. It is anticipated that the majority of patients will undergo surgical resection after their EUS.",[27],[308,309,310],"Confocal laser endomicroscopy","pancreatic cancer","IPMN","2025-08-18",{"date":313,"type":33},"2025-08-22",{"date":315,"type":33},"2018-10-01",{"date":317,"type":21},"2026-12-31",{"name":319,"class":40},"Ohio State University Comprehensive Cancer Center",10,{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":160,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":22,"phases":331,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":41},"100464987","determination-of-pancreatic-steatosis-prevalence-and-correlation-with-high-risk-cyst-features-100464987","NCT05334836","Determination of Pancreatic Steatosis Prevalence and Correlation With High-risk Cyst Features","Determination of Pancreatic Steatosis Prevalence and Correlation With High-risk Cyst Features in Patients With Pre-malignant Pancreatic Cystic Neoplasms Using Magnetic Resonance Imaging and Endoscopic Ultrasound","FPPCN","Inclusion Criteria:\n\n1. Age 18 or older\n2. Patients with at least 1 pancreatic cystic lesion presumed to be IPMN or MCN based on CT, MRI or EUS features, with a cyst size ≥ 5mm; or healthy subjects.\n3. Patients who are able to provide written informed consent to participate in the study and comply with the study procedures.\n\nExclusion Criteria:\n\n1. Unable to provide written informed consent\n2. Patients with metallic implants or other contraindications to MRI\n3. Patients with contraindications for endoscopy due to comorbidities\n4. Patients with known pancreatic cancer or prior pancreatic resection\n5. Patients with significant alcohol consumption, defined as alcohol intake of over 20 g daily (140 g weekly) for men and 10 g daily (70 g weekly) for women",{"count":330,"type":21},236,[266],"Pancreatic cancer is the fifth leading cause of cancer mortality in Hong Kong and the seventh leading cause of cancer mortality worldwide. In 2020, approximately 496000 new cases of pancreatic cancers were diagnosed globally . Pancreatic cancer is a highly fatal cancer with a case-fatality rate of 94.0% globally. In Hong Kong, both the incidence and mortality of pancreatic cancer have increased over the past decade.\n\nDue to the deep-seated location of pancreas, it is difficult to diagnose pancreatic cancer at an early stage, which in turn leads to delays in cancer treatment and poorer survival. Despite advances in oncologic treatment, the 5-year survival rate of metastatic pancreatic cancer remains poor (\\~2.9%). As such, there has been growing interest to improve pancreatic cancer prevention and survival by:\n\n1. reduction of modifiable risk factors (eg, cigarette smoking, obesity, diabetes),\n2. screening for early detection of high-risk pre-malignant lesions in selected high-risks patients with strong family history of pancreatic cancer and\u002For certain germline mutations of pancreatic cancer susceptibility genes (eg, BRCA1, BRAC2, DNA mismatch repair genes in Lynch Syndrome, etc) by magnetic resonance imaging (MRI) or endoscopic ultrasound (EUS), and\n3. surveillance of pre-malignant precursor lesions such as mucinous pancreatic cystic neoplasms (PCN) by imaging and\u002For EUS to identify high-risk neoplastic progression indicated for surgical resection.",[334,27],"Pancreatic Steatosis","2025-08-06",{"date":337,"type":33},"2025-08-11",{"date":339,"type":33},"2022-04-06",{"date":341,"type":21},"2026-04-30",{"name":343,"class":40},"Chinese University of Hong Kong",{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":350,"enrollmentInfo":351,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":353,"conditions":354,"keywords":356,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":41},"100559472","artificial-intelligence-in-endoscopic-ultrasound-100559472","NCT06564571","Artificial Intelligence in Endoscopic Ultrasound","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Any patient undergoing endoscopic ultrasound examination\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years","100 Years",{"count":352,"type":21},310,"The objective of the study is to determine if this artificial intelligence system is capable of detecting abnormalities in the pancreas that are identified by an endoscopist at endoscopic ultrasound procedures.",[61,355,27],"Pancreas Disease",[357,309,358,359],"pancreatic disease","pancreatic cyst","artificial intelligence","2025-05-27",{"date":362,"type":33},"2025-05-31",{"date":364,"type":33},"2024-01-19",{"date":366,"type":21},"2027-12",{"name":368,"class":40},"Orlando Health, Inc.",{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":376,"conditions":377,"keywords":378,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":41},"100305793","bio-repository-of-high-risk-cohorts-for-the-early-detection-of-pancreas-cancer-100305793","NCT03260842","Bio-Repository of High Risk Cohorts for the Early Detection of Pancreas Cancer","Inclusion Criteria:\n\n* Older than 18 with pancreas cyst\n* Older than 18 at high risk for Pancreas cancer\n\nExclusion Criteria:\n\n* Unable to provide consent\n* Not willing to provide bio-specimens",{"count":304,"type":21},"Bio-repository to collect bio-specimens from patients with 1) pancreatic cysts and 2) patients at high risk, defined by family history and\u002For genetic mutations, for pancreatic cancer.",[27,355],[379,380,381],"early detection","biomarkers","pancreas cancer","2025-03-26",{"date":384,"type":33},"2025-04-01",{"date":386,"type":33},"2017-09-01",{"date":388,"type":21},"2030-04-30",{"name":390,"class":40},"Stanford University",{"id":392,"slug":393,"hasResults":11,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":160,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":401,"conditions":402,"keywords":404,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":41},"100582735","prevalence-of-pancreatic-steatosis-in-pancreatic-cystic-neoplasms-and-pancreatic-adenocarcinoma-100582735","NCT06867172","Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma","The Emerging Issue - Pancreatic Steatosis Prevalence in Pancreatic Cystic Neoplasms and Adenocarcinoma: Insights From a Single-center Retrospective Study","SPACE","Inclusion Criteria:\n\n* Age 18 or older\n* Patients with at least 1 pancreatic cystic lesion based on CT and EUS features, with a cyst size ≥ 5mm; or healthy subjects or PDAC (confirmed by histopathological exam).\n\nExclusion Criteria:\n\n* No evidence of written informed consent\n* Patients with contraindications for endoscopy due to comorbidities\n* Metal stent in hepato-bilio-pancreatic region at time of baseline CT-imaging (vascular, luminal and biliary)\n* Acute pancreatitis at baseline imaging\n* Pancreatic surgery at baseline imaging in our department\n* Splenectomy\n* Patients with significant alcohol consumption, defined as alcohol intake of over 20 g daily (140 g weekly) for men and 10 g daily (70 g weekly) for women",{"count":400,"type":21},66,"Several pancreatic neoplastic cystic lesions, such as IPMN (intrapapilary mucinous neoplasia), cystic neuroendocrine tumors (NET) and mucinous neoplasms, present a carcinogenetic risk, though it is yet unknown if this risk is increased in patients with pancreatic steatosis (PS).\n\nThe primary objective of the study is to determine de prevalence of pancreatic steatosis in pancreatic neoplastic cysts and if pancreatic steatosis is increased in those lesions that pose a carcinogenetic risk.\n\nThe secondary objective is to evaluate the prevalence of pancreatic steatosis in pancreatic adenocarcinoma.",[334,27,403],"Pancreatic Adenocarcinoma",[405,406,407,408,409,410],"pancreas","steatosis","cyst","cancer","adenocarcinoma","fat","2025-03-06",{"date":413,"type":33},"2025-03-10",{"date":415,"type":33},"2019-01-01",{"date":417,"type":21},"2025-06-30",{"name":419,"class":40},"Carol Davila University of Medicine and Pharmacy",{"id":421,"slug":422,"hasResults":11,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":426,"eligibilityCriteria":427,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":430,"conditions":431,"keywords":433,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":41},"100570396","endocrine-metabolic-inflammatory-biomarkers-to-identify-highgrade-dysplasiainvasive-carcinoma-in-patients-with-ipmn-of-the-pancreas-100570396","NCT06706700","Endocrine, Metabolic, Inflammatory Biomarkers to Identify Highgrade Dysplasia\u002Finvasive Carcinoma in Patients with IPMN of the Pancreas","Definition of Radiological and Endocrine\u002Fmetabolic\u002Finflammatory Biomarker(s) to Identify Highgrade Dysplasia\u002Finvasive Carcinoma in Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas","EMI-IPMN","cohort A: inclusion criteria:\n\n* histologically proven IPMNs with full pathological data (type of IPMNs, grade of dysplasia; for invasive IPMNs: grading, pTNM classification, presence of perineural (microvascular infiltration)\n* availability of clinical and imaging criteria for surgical resections defined by International and European guidelines (worrisome features and high-risk stigmata according to International Guidelines and absolute\u002Frelative criteria for surgery according to European guidelines\n* age ≥18 years\n\nexclusion criteria:\n\n\\- lack of preoperative clinical and radiological data according the two guidelines\n\nCohort B and C:\n\ninclusion criteria:\n\n* Age \\>= 18 years\n* Charlson comorbidity index \\\u003C7\n* indication for surgery for suspected IPMN",{"count":429,"type":21},586,"Under the hypotheses that a more accurate patients selection could limit the problem of overtreatment and that benign intraductal papillary mucinous neoplasms (IPMN) have a distinguishable Endocrine\u002FMetabolic\u002FInflammatory (EMI) profile from those with high-grade disease\u002Finvasive carcinoma, this study has three specific aims. The first aim is to evaluate and confirm the accuracy of the updated versions of International and European guidelines for the management of IPMN and it will be addressed by retrospectively applying the criteria included in the two guidelines on 350 patients with resected IPMN in order to determine the most accurate criteria to identify High Grade Dysplasia(HGD)\u002FInvasive Carcinoma (IC).\n\nThe second aim is to identify pre-operative biological and\u002For radiological\u002Fendosonographic biomarker(s) able to distinguish low- versus high-risk IPMN for cancer progression in a prospective study by enrolling a cohort of 186 (of which 145 surgically-resected) patients.\n\nThe third aim is to prospectively validate biological and\u002For radiological\u002Fendosonographic biomarker(s) (previously identified and optimized) on a new cohort of 50 patients with IPMN undergoing surgical resection.",[432,27],"Intraductal Papillary Mucinous Neoplasm of Pancreas",[434,435,436],"ipmn","intraductal papillary mucinous neoplasm of the pancreas","Pancreatic Cysts","2024-11-22",{"date":439,"type":33},"2024-11-26",{"date":441,"type":33},"2020-07-13",{"date":443,"type":21},"2025-03-31",{"name":445,"class":40},"IRCCS San Raffaele",{"id":447,"slug":448,"hasResults":11,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":350,"enrollmentInfo":453,"targetDuration":4,"studyType":22,"phases":455,"briefSummary":456,"conditions":457,"keywords":465,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":473,"leadSponsor":474,"locationsCount":41},"100542265","eus-examination-using-endosound-vision-system-vs-standard-echoendoscope-100542265","NCT06340620","EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope","Randomized Trial of Endoscopic Ultrasound Examination Using EndoSound Vision System vs. Standard Echoendoscope","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Any patient undergoing EUS examination for evaluation of the pancreas, bile duct, mediastinal or intraabdominal lymph nodes, or luminal lesions in the esophagus, stomach, duodenum or colon.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Unable to obtain consent for the procedure from either the patient or LAR.\n* Intrauterine pregnancy.",{"count":454,"type":21},140,[266],"This is a randomized trial to compare the standard echoendoscope with the newly developed EndoSound Visual System in the evaluation of lesions in the gastrointestinal tract.",[458,61,27,459,460,461,462,463,464],"Pancreatic Disease","Gastrointestinal Tumor","Bile Duct Diseases","Bile Duct Cancer","Lymph Node Disease","Submucosal Tumor of Gastrointestinal Tract","Gastrointestinal Cancer",[466,467,468],"Endoscopic ultrasound","EndoSound Vision System","Randomized trial","2024-03-25",{"date":471,"type":33},"2024-04-01",{"date":469,"type":21},{"date":366,"type":21},{"name":368,"class":40},{"id":476,"slug":477,"hasResults":11,"nctId":478,"briefTitle":479,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":482,"conditions":483,"keywords":4,"overallStatus":484,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":109},"100531139","genomic-profiling-of-pancreatic-cystic-tumors-100531139","NCT06195904","Genomic Profiling of Pancreatic Cystic Tumors","Inclusion Criteria:\n\n* Pancreatic cyst patients undergoing cyst aspiration or biopsy or surgical resection\n* Patients who gave written informed consent\n\nExclusion Criteria:\n\n* Anyone who has not signed a written consent form.\n* Patients deemed unsuitable for research (severe infection, drug abuse, severe mental illness, etc.)",{"count":241,"type":21},"This study aims to find out whether quantitative and qualitative analysis, including genetic mutation analysis, of samples obtained from patients with pancreatic cysts is associated with the risk of malignancy, and helpful in the differential diagnosis of mucinous and serous cysts. The study design is a single-arm prospective cohort observational study. Using blood, pancreatic cyst fluid, and pancreatic cyst tissue, genetic mutation analysis and measurement of various biomarkers are performed, and the relationship between these and malignancy or whether they are helpful in distinguishing mucinous and serous cysts is analyzed. The primary outcome is genetic variants of pancreatic cysts associated with malignancy. The secondary outcomes are factors including genetic variants that differentiate mucinous from serous cysts.",[27],"NOT_YET_RECRUITING","2023-12-23",{"date":487,"type":33},"2024-01-08",{"date":489,"type":21},"2024-01-15",{"date":491,"type":21},"2030-05-15",{"name":493,"class":40},"Samsung Medical Center",{"id":495,"slug":496,"hasResults":11,"nctId":497,"briefTitle":498,"officialTitle":498,"acronym":499,"eligibilityCriteria":500,"healthyVolunteers":160,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":501,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":503,"conditions":504,"keywords":507,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":41},"100520318","improving-pancreatic-cancer-care-by-the-use-of-computational-science-and-technology-100520318","NCT06055010","Improving Pancreatic Cancer Care by the Use of Computational Science and Technology","IMPACT","Inclusion Criteria:\n\n* ≥18 years of age\n* Patients who received diagnostic procedures and\u002For treatment for (suspected) benign and malignant pancreatic lesions as registered in the Dutch Pancreatic Cancer Project (PACAP) audit database and healthy individuals who received an abdominal CT-scan (controls)\n\nExclusion Criteria:\n\n\\- Subjects who object to the use of their data for the purpose of scientific research",{"count":502,"type":21},5000,"The goal of the IMPACT project is to set up a data sharing infrastructure between expert centers for pancreatic surgery that enables training, testing and validation of computer science tools to improve quality of care for patients with pancreatic cancer.",[61,27,403,165,505,506],"Pancreas Adenocarcinoma","Pancreas Cyst",[508,509,510,61],"Artificial Intelligence","Data Science","Computer Science","2023-09-22",{"date":513,"type":33},"2023-09-26",{"date":515,"type":33},"2014-01-01",{"date":517,"type":21},"2029-12-31",{"name":519,"class":40},"UMC Utrecht"]